Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions

Comprehensive studies of pharmacokinetics and biodistribution of indocyanine green and liposomal indocyanine green by multispectral optoacoustic tomography

(2015) Wantong Song et al.   RSC Advances

Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency

(2014) Edward A. Sykes et al.   ACS Nano

Integration of Nanoassembly Functions for an Effective Delivery Cascade for Cancer Drugs

(2014) Qihang Sun et al.   ADVANCED MATERIALS

A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections

(2014) Peng Liu et al.   ANTI-CANCER DRUGS

PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment

(2014) Hecheng Ma et al.   BIOMATERIALS

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

(2014) F A L M Eskens et al.   BRITISH JOURNAL OF CANCER

EPR: Evidence and fallacy

(2014) Joseph W. Nichols et al.   JOURNAL OF CONTROLLED RELEASE

Co-Delivery of Doxorubicin and siRNA with Reduction and pH Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

(2014) Weicai Chen et al.   Small

Tumor Vasculature Targeting: A Generally Applicable Approach for Functionalized Nanomaterials

(2014) Feng Chen et al.   Small

Parkin regulates kainate receptors by interacting with the GluK2 subunit

(2014) AnnaMaria Maraschi et al.   Nature Communications

Facing the Truth about Nanotechnology in Drug Delivery

(2013) Kinam Park   ACS Nano

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

(2013) C. Sessa et al.   CLINICAL CANCER RESEARCH

Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice

(2013) Darren Lars Stirland et al.   JOURNAL OF CONTROLLED RELEASE

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

(2013) Anna K. Nowak et al.   LUNG CANCER

Nanoparticle Delivered Vascular Disrupting Agents (VDAs): Use of TNF-Alpha Conjugated Gold Nanoparticles for Multimodal Cancer Therapy

(2013) Mithun M. Shenoi et al.   MOLECULAR PHARMACEUTICS

Superior Penetration and Retention Behavior of 50 nm Gold Nanoparticles in Tumors

(2012) S. Huo et al.   CANCER RESEARCH

Fast Multispectral Optoacoustic Tomography (MSOT) for Dynamic Imaging of Pharmacokinetics and Biodistribution in Multiple Organs

(2012) Adrian Taruttis et al.   PLoS One

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

(2011) M. Zweifel et al.   ANNALS OF ONCOLOGY

Targeted drug delivery to tumors: Myths, reality and possibility

(2011) You Han Bae et al.   JOURNAL OF CONTROLLED RELEASE

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

(2010) Michelle Head et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles

(2010) Helen Lee et al.   MOLECULAR PHARMACEUTICS

Preclinical and clinical studies of anticancer agent-incorporating polymer micelles

(2009) Yasuhiro Matsumura et al.   CANCER SCIENCE

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

(2009) Dietmar W Siemann et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mediating Tumor Targeting Efficiency of Nanoparticles Through Design

(2009) Steven D. Perrault et al.   NANO LETTERS

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

(2008) Patricia M. LoRusso et al.   INVESTIGATIONAL NEW DRUGS

Nanoparticle therapeutics: an emerging treatment modality for cancer

(2008) Mark E. Davis et al.   NATURE REVIEWS DRUG DISCOVERY